Methods and compositions for treatment and control of plant disease

Patent metadata

Field	Value
Publication number	US-10499650-B2
Application number	US-201314433852-A
Country	US
Kind code	B2
Filing date	Oct 18, 2013
Priority date	Oct 19, 2012
Publication date	Dec 10, 2019
Grant date	Dec 10, 2019

Abstract

The present invention provides methods for development of a virulent bacteriophage-based treatment for the control of plant diseases caused by Xylella fastidiosa. The invention further provides methods of isolating and propagating bacteriophage virulent to X. fastidiosa in a Xanthomonas bacterial host and for treating or reducing symptoms of X. fastidiosa infection in a plant. The invention further provides methods of isolating and propagating bacteriophage virulent to Xanthomonas axonopodis pv. citri and for treating or reducing symptoms of Xanthomonas axonopodis pv. citri infection in a plant.

First claim

The invention claimed is:

1. A plant disease biocontrol composition formulated for delivery to a plant, the composition comprising at least one carrier comprising a pH buffering agent, and at least two bacteriophage isolates of Xfas100 phage type or Xfas300 phage type, or both; wherein each of said bacteriophage isolates is virulent to Xylella fastidiosa and Xanthomonas species, and the bacteriophages are capable of lysing said Xylella fastidiosa or Xanthomonas bacteria, further wherein
the Xfas100 phage type displays the following characteristics:
(a) the bacteriophage infects a cell by binding to a Type IV pilus;
(b) the bacteriophage comprises a non-contractile tail and a capsid size ranging from 55-77 nm in diameter and belongs to the Siphoviridae family;
(c) the genomic size of the bacteriophage is about 55500 bp to 56200 bp; and
(d) the bacteriophage prevents or reduces symptoms associated with Pierce's Disease in a plant or plants;
and further wherein the Xfas300 phage type displays the following characteristics:
(e) the bacteriophage infects a cell by binding to a Type IV pilus;
(f) the bacteriophage comprises a non-contractile tail and a capsid size ranging from 58-68 nm in diameter and belongs to the Podoviridae family;
(g) the genomic size of the bacteriophage is about 43300 bp to 44600 bp; and
(h) the bacteriophage prevents or reduces symptoms associated with Pierce's Disease in a plant or plants.

2. The plant disease biocontrol composition of claim 1 , wherein the Xfas100 phage type comprises Xfas103 or Xfas106, or both; and the Xfas300 phage type comprises at least one bacteriophage selected from the group consisting of Xfas302, Xfas303, Xfas304, and Xfas306 wherein representative samples of said phage types have been deposited under ATCC Accession Numbers PTA-13096, PTA-13095, PTA-13098, PTA-13099, PTA-13100, and PTA-13097, respectively, for phages Xfas103, Xfas106, Xfas302, Xfas303, Xfas304, and Xfas306; or wherein the Xfas100 phage type comprises a genome with a DNA sequence of SEQ ID NO: 13 or SEQ ID NO: 16; and the Xfas300 phage type comprises a genome with a DNA sequence selected from the group consisting of SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, and SEQ ID NO:24.

3. The composition of claim 1 , further defined as being formulated for introduction to a plant via injection, spraying, misting, or dusting.

4. The composition of claim 3 , further defined as being formulated for introduction to a plant via injection.

5. The composition of claim 1 , wherein the concentration of bacteriophage is from 1×10 7 to 1×10 12 pfu/mL.

Assignees

• Texas A & M Univ Sys

Inventors

• Gonzalez Carlos F
• Ahern Stephen J
• Das Mayukh
• Young Iii Ryland F
• Bhowmick Tushar Suvra

Classifications

• C12N2795/10221

  Viruses as such, e.g. new isolates, mutants or their genomic sequences · CPC title

• C12N2795/10251

  Methods of production or purification of viral material · CPC title

• C12N2795/10231

  Uses of virus other than therapeutic or vaccine, e.g. disinfectant · CPC title

• C12N2795/10331

  Uses of virus other than therapeutic or vaccine, e.g. disinfectant · CPC title

• C12N2795/10233

  Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory · CPC title